基于生物信息学分析LIX1基因在前列腺癌中的表达与免疫浸润的关系
Expression and Immune Infiltration of LIX1 in Prostate Cancer Based on Bioinformatics
DOI: 10.12677/ACM.2023.131024, PDF,    科研立项经费支持
作者: 黎金连:桂林医学院智能医学与生物技术学院遗传教研室,广西 桂林;南宁中心血站,中国医学科学院输血研究所–南宁中心血站输血传播疾病(TTD)联合实验室,广西 南宁;周青鸟:广西医科大学基础医学院生物化学与分子生物学教研室,广西 南宁;林 军, 吴群英*:桂林医学院智能医学与生物技术学院遗传教研室,广西 桂林
关键词: LIX1前列腺癌预后标记物TCGA数据库免疫浸润LIX1 Prostate Cancer Prognostic Marker TCGA Database Immune Infiltration
摘要: 目的:探讨肢体和中枢神经系统表达因子1 (Limb and CNS expressed 1, LIX1)在前列腺癌(prostate cancer, PCa)中的表达及临床意义。方法:利用Oncomine和UALCAN数据库分析LIX1在PCa组织中的表达;利用R3.6.3软件绘制受试者工作特征曲线(Receiver Operating Characteristic curve,ROC曲线)和临床基线表,分析LIX1表达与PCa患者临床特征参数的关系;应用CANCERTOOL、GEPIA和TIMEER数据库分析LIX1表达水平与PCa患者预后及其与免疫细胞浸润的关系。利用LinkedOmics数据库筛选LIX1共表达基因及进行GSEA分析,探讨LIX1在PCa中潜在作用的信号通路。结果:LIX1 mRNA在PCa组织中表达水平显著降低且对PCa的诊断具有一定准确性。LIX1表达水平与PCa患者的TNM分期、Gleason分期、年龄和PSA水平显著负相关。LIX1低表达患者预后不佳,具有更高的复发风险。LIX1表达水平与PCa巨噬细胞的浸润水平呈正相关。LIX1及其共表达的基因主要富集在线粒体呼吸链复合物的组装,胞质分裂,核糖体和细胞周期途径等信号通路。结论:LIX1在PCa中表达降低,且与免疫浸润有关,可作为PCa诊断和不良预后的新型标志物。
Abstract: Objective: To reveal the expression and clinical features of Limb and CNS expressed 1 (LIX1) in prostate cancer (PCa). Methods: We used Oncomine and UALCAN databases to analyze the expres-sion of LIX1 in PCa. The Receiver Operating Characteristic curve (ROC) and baseline clinical charac-teristics of LIX1 were plotted by R3.6.3 package, and the relationship between LIX1 expression and clinical characteristics of PCa patients was also identified. Then, we applied CANCERTOOL, GEPIA and TIMEER databases to explore the expression and clinical outcomes, and the correlation with immune infiltration of LIX1 in PCa. Meanwhile, LinkedOmics database was used to identify co-expression genes of LIX1, and then we performed the Gene Set Enrichment Analysis (GSEA) to explore the potential signaling pathway. Results: The expression level of LIX1 in PCa tissues was significantly reduced and the diagnosis of PCa was accurate. The expression level of LIX1 was signif-icantly negatively correlated with PCa patients’ TNM grade, Gleason scores, age and PAS level. Low LIX1 had worsened disease-free survival and a higher risk of recurrence of PCa patients, and was positive related to the abundance of macrophages. GSEA suggests that LIX1 genes are mainly con-centrated in mitochondria respiratory chain complex assembly, cytokinesis, ribosomes and cell cy-cle pathways. Conclusion: The expression of LIX1 is decreased in PCa and is associated with immune infiltration, which can be used as a novel marker for PCa diagnosis and poor prognosis.
文章引用:黎金连, 周青鸟, 林军, 吴群英. 基于生物信息学分析LIX1基因在前列腺癌中的表达与免疫浸润的关系[J]. 临床医学进展, 2023, 13(1): 152-162. https://doi.org/10.12677/ACM.2023.131024

参考文献

[1] Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. [Google Scholar] [CrossRef] [PubMed]
[2] Feng, R.M., Zong, Y.N., Cao, S.M., et al. (2019) Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics? Cancer Communications (London), 39, 22. [Google Scholar] [CrossRef] [PubMed]
[3] Hou, Q., Bing, Z.-T., Hu, C., et al. (2018) RankProd Com-bined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer. EBioMedicine, 32, 234-244. [Google Scholar] [CrossRef] [PubMed]
[4] McKey, J., Martire, D., de Santa Barbara, P., et al. (2016) LIX1 Regulates YAP1 Activity and Controls the Proliferation and Differentiation of Stomach Mesenchymal Progenitors. BMC Biology, 14, 34. [Google Scholar] [CrossRef] [PubMed]
[5] Zou, J., Zhu, X., Xiang, D., et al. (2021) LIX1-Like Protein Pro-motes Liver Cancer Progression via miR-21-3p-Me- diated Inhibition of Fructose-1,6-Bisphosphatase. Acta Pharmaceu-tica Sinica B, 11, 1578-1591. [Google Scholar] [CrossRef] [PubMed]
[6] Rhodes, D.R., Kalyana-Sundaram, S., Mahavisno, V., et al. (2007) Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles. Neoplasia (New York, NY), 9, 166-180. [Google Scholar] [CrossRef] [PubMed]
[7] Chandrashekar, D.S., Bashel, B., Balasubramanya, S.A.H., et al. (2017) UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (New York, NY), 19, 649-658. [Google Scholar] [CrossRef] [PubMed]
[8] Tang, Z., Li, C., Kang, B., Gao, G., et al. (2017) GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Research, 45, W98-W102. [Google Scholar] [CrossRef] [PubMed]
[9] Cortazar, A.R., Torrano, V., Martín-Martín, N., et al. (2018) CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer Datasets. Cancer Research, 78, 6320-6328. [Google Scholar] [CrossRef
[10] Li, T., Fu, J., Zeng, Z., Cohen, D., et al. (2020) TIMER2.0 for Analysis of Tumor-Infiltrating Immune Cells. Nucleic Acids Research, 48, W509-W514. [Google Scholar] [CrossRef] [PubMed]
[11] Vasaikar, S.V., Straub, P., Wang, J., et al. (2018) LinkedOmics: Analyz-ing Multi-Omics Data within and across 32 Cancer Types. Nucleic Acids Research, 46, D956-D963. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, R., Wu, Y., Yu, J., et al. (2020) Plasma Messenger RNAs Identi-fied through Bioinformatics Analysis Are Novel, Non-Invasive Prostate Cancer Biomarkers. OncoTargets and Therapy, 13, 541-548. [Google Scholar] [CrossRef
[13] Sinnott, J.A., Peisch, S.F., Tyekucheva, S., et al. (2017) Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clinical Cancer Research, 23, 81-87. [Google Scholar] [CrossRef
[14] Kang, Y., Song, P., Fang, K., et al. (2020) Survival Out-comes of Low Prostate-Specific Antigen Levels and T Stages in Patients with High-Grade Prostate Cancer: A Popula-tion-Matched Study. Journal of Cancer, 11, 6484-6490. [Google Scholar] [CrossRef] [PubMed]
[15] 伊丽努尔•艾力, 李辉. 临床各指标及不同影像学检查参数与前列腺癌Gleason评分的相关性[J]. 新疆医学, 2019, 49(8): 822-825.
[16] Bechis, S.K., Carroll, P.R. and Cooperberg, M.R. (2011) Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 235-241. [Google Scholar] [CrossRef
[17] Hollemans, E., Verhoef, E.I., Bangma, C.H., et al. (2021) Cribri-form Architecture in Radical Prostatectomies Predicts Oncological Outcome in Gleason Score 8 Prostate Cancer Patients. Modern Pathology, 34, 184-193. [Google Scholar] [CrossRef] [PubMed]
[18] Wu, Z., Chen, H., Luo, W., et al. (2020) The Landscape of Im-mune Cells Infiltrating in Prostate Cancer. Frontiers in Oncology, 10, Article ID: 517637. [Google Scholar] [CrossRef] [PubMed]